Clinical Trial Update: Phase 1 Clinical Study of GT-220F in Subjects With Metastatic Castration Resistant Prostate Cancer (mCRPC) [Phase 1]

View source ↗

Summary

Geode Therapeutics is conducting a Phase 1 study of GT-220F for metastatic castration-resistant prostate cancer, currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• GT-220F

Snippet

Sponsor: Geode Therapeutics Inc. | Conditions: Metastatic Castration Resistant Prostate Cancer | Phase 1 | Status: NOT_YET_RECRUITING